CJC-1295
CJC-1295 (Modified GRF 1-29, with or without DAC)
Research Parameters
- Typical Dose Range
- No DAC: 100 mcg, 1 to 3 times daily (before bed, post-workout). With DAC: 1 to 2 mg once or twice weekly.
- Half-Life
- No DAC: ~30 minutes. With DAC: ~6 to 8 days.
- Administration Route
- Subcutaneous
Dosing information is for research purposes only and has not been evaluated by the FDA.
If Ipamorelin is the trigger for a growth hormone pulse, CJC-1295 is the amplifier. Alone, it raises baseline GH and IGF-1 over weeks. Paired with Ipamorelin, which is how you'll almost always see it in research, it produces a larger, cleaner GH release than either peptide alone. That's the reason CJC-1295 + Ipamorelin is the most-studied GH secretagogue stack in the peptide research world.
It comes in two forms and picking between them is the first thing to understand. CJC-1295 without DAC is short-acting. Researchers use it for natural GH pulsing, multiple times per day. CJC-1295 with DAC is long-acting, dosed once or twice a week, used when research protocols aim for steady elevation rather than pulsing. Different tools for different research questions.
For research purposes only.
Mechanism of Action
CJC-1295 is a modified version of growth hormone-releasing hormone (GHRH). The DAC variant carries a drug affinity complex that binds to albumin in the blood, stretching the half-life from around 30 minutes to about a week. Both variants stimulate pulsatile GH release from the pituitary; the DAC variant also sustains basal GH and IGF-1 elevation.
Citations
Frequently Asked Questions
- What is the difference between CJC-1295 with DAC and without DAC?
DAC (Drug Affinity Complex) binds CJC-1295 to albumin in the blood, stretching its half-life from roughly 30 minutes to around a week. Research using no-DAC aims to mimic natural GH pulsing; DAC research aims for steady elevation. For research purposes only.
- Why is CJC-1295 studied alongside Ipamorelin?
CJC-1295 tells the pituitary to release more GH when triggered; Ipamorelin is the trigger. Research shows the combination produces a larger, cleaner GH pulse than either compound alone. For research purposes only.
- What is the typical research protocol for CJC-1295?
Research protocols run 8 to 12 weeks. No-DAC is dosed 1 to 3 times daily to match endogenous pulses; DAC is dosed once or twice weekly. Both are typically paired with Ipamorelin. For research purposes only.